secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2025-07-22T23:59:59+00:00
Accession:  0001835268-25-000047
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma appoints James A. Schoeneck to board of directors
-------------------------------------------------------------------

- Board size increased from six to seven; Schoeneck appointed effective July 22, 2025.
- Schoeneck is former CEO of Depomed (2011-2017) and BrainCells (2005-2011).
- Currently serves as independent director and chairman at FibroGen and Calidi Biotherapeutics.
- Board determined Schoeneck is independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000047/0001835268-25-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000047/cntb-20250722.htm
  HTML page:      https://secwatch.observer/filing/0001835268-25-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer